Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ronald Andre Wohl is active.

Publication


Featured researches published by Ronald Andre Wohl.


Journal of The Chemical Society-perkin Transactions 1 | 1991

(3S)-3-hydroxyquinidine, the major biotransformation product of quinidine. Synthesis and conformational studies. X-Ray molecular structure of (3S)-3-hydroxyquinidine methanesuiphonate

F. Ivy Carroll; Philip Abraham; Kevan Gaetano; S. Wayne Mascarella; Ronald Andre Wohl; Joan M. Lind; Karl Petzoldt

(3S)-3-Hydroxyquinidine, the major metabolite of the Cinchona alkaloid quinidine, was prepared by synthetic chemical modification or microbial oxidation of quinidine. The structure of this metabolite has been demonstrated to be (3S)-3-hydroxyquinidine by 1H and 13C NMR, IR, UV and mass spectral analysis. Previously published comparisons of the 13C NMR spectra of 3-hydroxyquinidine and model compounds were used to establish the absolute stereochemistry of the metabolite (see ref. 8). This assignment has been verified by single-crystal X-ray analysis of (3S)-3-hydroxyquinidine methanesulphonate. The gas- and solution-phase conformational preference of the metabolite derived from molecular modelling and NOE studies are compared with the conformation observed by X-ray crystallography.


Journal of Medicinal Chemistry | 1987

Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agents.

Lumma Wc; Ronald Andre Wohl; David D. Davey; Thomas M. Argentieri; DeVita Rj; Robert P. Gomez; Jain Vk; Marisca Aj; Thomas K. Morgan; Reiser Hj


Archive | 1985

Substituted sulfonamidobenzamides, antiarrhythmic agents and compositions thereof

David D. Davey; William C. Lumma; Ronald Andre Wohl


Archive | 1989

Derivatized alkanolamines as cardiovascular agents

Randall Lis; William C. Lumma; Thomas Kenneth Morgan; Klaus Nickisch; Ronald Andre Wohl


Archive | 1987

Substituted 4-[1H-Imidazol-1-yl] benzamides as antiarrhythmic agents

Klaus Nickisch; Randall Lis; William C. Lumma; Thomas Kenneth Morgan; Ronald Andre Wohl


Journal of Medicinal Chemistry | 1990

Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1-yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities

Thomas K. Morgan; Randall Lis; William C. Lumma; Ronald Andre Wohl; Klaus Nickisch; Gary B. Phillips; Joan M. Lind; John W. Lampe; Susan V. Di Meo


Archive | 1985

Substituted sulfonamidobenzamides and method of treating arrhythmias

David D. Davey; William C. Lumma; Ronald Andre Wohl


Archive | 1989

Novel-N-(4-(Aminosubstituted)phenyl) methanesulfonamides and their use as cardiovascular agents

Stanley Shimen Greenberg; William C. Lumma; Klaus Nickisch; Ronald Andre Wohl


Journal of Medicinal Chemistry | 1990

Synthesis and cardiac electrophysiological activity of aryl-substituted derivatives of the class III antiarrhythmic agent sematilide. Potential class I/III agents.

Gary Phillips; Thomas K. Morgan; Klaus Nickisch; Joan M. Lind; Robert P. Gomez; Ronald Andre Wohl; Thomas M. Argentieri; Mark E. Sullivan


Archive | 1984

Imidazolium salts, intermediates thereto and their use

Julius Diamond; William C. Lumma; Thomas Kenneth Morgan; Ronald Andre Wohl

Collaboration


Dive into the Ronald Andre Wohl's collaboration.

Top Co-Authors

Avatar

William C. Lumma

United States Military Academy

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Randall Lis

Bayer HealthCare Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David D. Davey

Bayer HealthCare Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar

Alfred Arthur Hagedorn

Bayer HealthCare Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar

Thomas K. Morgan

Bayer HealthCare Pharmaceuticals

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge